FDA Drops New Oncology Development Guidelines
The FDA released a trio of documents covering tissue-agnostic development, adverse reactions caused by immunotherapies, and acute myeloid leukemia (AML) development guidelines to maintain high drug development standards. The first two documents are additional drafts, revising content from years prior, and the AML development document is a final version, though all three include nonbinding recommendations.
Tissue-Agnostic Drug Development in Oncology
Instead of targeting a specific cancer type isolated in a certain tissue or organ, tissue-agnostic therapies can target mutation alterations across multiple cancer types. Tissue-agnostic cancer drugs have the potential to be more flexible for patient needs and open the opportunity to address several cancer types as opposed to just one.
It's free! Log in now to read
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115